Skip to main content

Table 3 TOI Association with Achieving a DR (per Endpoint Assessment Committee)a

From: Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Improvement Magnitude, Points Improvement Duration, Cycles TOI Improvement Rate, Odds Ratiob (95% CI)
5 1 2.8 (1.1–7.0)
3 2.6 (1.0–6.9)
6 1 3.0 (1.2–7.8)
3 2.9 (1.1–8.1)
4 3.1 (1.1–9.1)
7 1 3.1 (1.2–8.4)
2 2.8 (1.1–7.6)
3 3.0 (1.0–9.4)
8 1 3.1 (1.1–8.5)
2 2.8 (1.0–7.8)
  1. DR durable response, TOI Trial Outcome Index
  2. aIntent-to-treat landmark analysis patients with ≥9 months’ follow-up evaluable for TOI improvement were included; only odds ratio of TOI improvement rates with corresponding P values <0.05 are shown. Full results are available in Additional file 1: Material
  3. bOdds ratio (DR/non-DR) stratified by disease stage (IIIB/IIIC/IVM1a versus IVM1b/IVM1c) and line of therapy (first-line versus second-line or later therapy)